Zentalis Pharmaceuticals, Inc.

ZNTL Nasdaq SEC CIK 1725160
Follow Zentalis Pharmaceuticals Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$28.8M −8% vs same quarter last year
EPS, diluted −$0.34 +8.1% vs same quarter last year
Operating cash flow −$32.7M −21.3% vs same quarter last year
Operating income −$31.2M +7.6% vs same quarter last year
Revenue by quarter
$26.9M
$0
$0
$0
$0
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income8 fiscal years
  • Revenue
  • Net income
−$300M−$200M−$100M$0$100MFY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$0−$137.1M
FY24$67.4M−$165.9M
FY23$0−$292.3M
FY22$0−$236.8M
FY21-−$158.7M
FY20-−$117.8M
FY19-−$45.7M
FY18--
Free cash flowOperating cash flow minus capital expenditure
−$300M−$200M−$100M$0FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$125.2M
FY24−$171.1M
FY23−$208.4M
FY22−$166.3M
FY21−$160.2M
FY20−$87.6M
FY19−$39.5M
FY18-
Returned to shareholdersDividends paid and shares bought back
$0$2.5M$5M$7.5M$10MFY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearBuybacks
FY25$10M
FY24$0
FY23$0
FY22-
FY21-
FY20-
FY19-
FY18-